LY4064809

LY4064809 is an investigational, orally bioavailable small molecule inhibitor developed by Eli Lilly and Company that specifically targets the KRAS G12D mutation. KRAS is a member of the RAS family of GTPases that acts as a molecular switch in cell signaling pathways; mutations such as G12D result in constitutive activation, driving the progression of various solid tumors, including pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. LY4064809 is designed to selectively bind to the mutant KRAS G12D protein, thereby inhibiting downstream oncogenic signaling through pathways such as MAPK/ERK and PI3K/AKT. It is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and pharmacokinetics in patients with advanced solid tumors harboring the KRAS G12D mutation, including studies comparing different oral formulations to optimize its bioavailability.